Very high levels of drug resistance seen in people experiencing first-line antiretroviral therapy failure in Kenya

Gus Cairns

A cross-sectional survey of viral load in patients attending the largest clinic providing antiretroviral therapy (ART) in Kenya has shown that after an average of nearly two years on first-line, tenofovir-based ART, 76% maintained a viral load under 40 copies/ml and 85% under 1000 copies/ml, the World Health Organization threshold for significant clinical and transmission consequences.

The study also found that tenofovir-based ART was more successful in patients who had been on previous ART and switched to the present regimen; 93% of them had viral loads under 40% and 99% under 1000 copies/ml.

However, the study found extremely high rates of significant drug resistance in those whose viral load was detectable. Eighty-nine per cent of first-line patients tested had mutations conferring resistance to drugs in at least one class of antiretrovirals and 83% to two or more classes. The K65R mutation, which confers resistance to all other drugs of the NRTI class except zidovudine, was present in more than two-thirds of patients – considerably in excess of its prevalence in patients tested for resistance in higher-income settings. The resistance patterns seen effectively ruled out future treatment success with all available NNRTI drugs as well as all NRTI drugs except zidovudine (AZT).

The high resistance rates seen underline the importance of adopting viral load testing more widely in low-income settings, as the biggest contributor to resistance was that patients may have been on failing therapy for up to two years before failure was detected.

The fact that average CD4 cell counts were lower in patients failing ART and even lower in patients with viral loads high enough to test for resistance show that while CD4 monitoring may still have a part to play in flagging up treatment failure, the lack of a means to detect virological failure has real clinical consequences.

June 1, 2016
Year of publication
2016
Resource types
Journal and research articles
Tags
Kenya, viral load, treatment, ART, ARVs, antiretroviral therapy, antiretroviral drugs, first-line treatment, treatment failure, drug resistance, viral load testing, CD4 monitoring, virological failure

Similar Resources

Antiretroviral therapy (ART) that enables suppression of HIV replication has been successfully rolled out at large scale to HIV-positive patients in low-income and middle-income countries.

HIV drug resistance (HIVDR) poses a threat to future antiretroviral therapy success. Monitoring HIVDR patterns is of particular importance in populations such as sex workers (SWs), where documented HIV prevalence is between 34-89%, and in countries with limited therapeutic options.

The longitudinal rate and profile of cognitive decline in persons with stable, treated, and virally suppressed HIV infection is not established.

HIV eradication and remission research has largely taken place in high-income countries. In low- and middle-income countries (LMIC), there may be factors that have a substantial impact on the size of the latent HIV reservoir and the immunological response to infection.

The Southern African HIV Clinicians Society’s biannual conference, held in Johannesburg, South Africa, from 24-27 October 2018, focused on clinical content for HIV and TB health care workers in the region and featured a wide range of topics…

CD4 cell count is an important test in HIV programs for baseline risk assessment, monitoring of ART where viral load is not available, and, in many settings, antiretroviral therapy (ART) initiation decisions.

The frequency of routine monitoring for people treated with antiretrovirals with viral suppression can be safely reduced from every three months, to every six months, investigators from Europe and the United States report in the June 1st edition of the Journal of Acquired Immune Deficiency…

Adolescents newly diagnosed with HIV need to be rapidly incorporated into HIV care networks to have the best chances of remaining in care in the long term, research from the United States published in the June 1st edition of the Journal of Acquired Immune Deficiency Syndromes shows.

BACKGROUND:

Attrition along the HIV care continuum slows gains in mitigating the South African HIV epidemic. Understanding population-level gaps in HIV identification, linkage, retention in care and viral suppression is critical to target programming.